Is GUTS or ESLA more profitable?

Estrella Immunopharma's return on equity of 0.00% beat Fractyl Health's return on equity. Company Net Margins Return on Equity Return on Assets Fractyl Health N/A -1,362.10% -84.89% Estrella Immunopharma N/A N/A -328.72%

Do analysts prefer ESLA or AADI?

Estrella Immunopharma currently has a consensus target price of $8.00, indicating a potential upside of 1,112.86%. Given Estrella Immunopharma's stronger consensus rating and higher probable upside, analysts plainly believe Estrella Immunopharma is more favorable than Aadi Bioscience. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Estrella Immunopharma 1 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00 Aadi Bioscience 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

Which has stronger earnings & valuation, ONCY or ESLA?

Estrella Immunopharma is trading at a lower price-to-earnings ratio than Oncolytics Biotech, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Oncolytics Biotech N/A N/A -$28.76M -$0.34 N/A Estrella Immunopharma N/A N/A -$13.06M -$0.24 N/A

Is ONCY or ESLA more profitable?

Estrella Immunopharma's return on equity of 0.00% beat Oncolytics Biotech's return on equity. Company Net Margins Return on Equity Return on Assets Oncolytics Biotech N/A -2,185.97% -442.99% Estrella Immunopharma N/A N/A -328.72%

Estrella Immunopharma (ESLA) Competitors

$0.66 -0.01 (-1.99%)

Closing price 09/11/2026 03:59 PM Eastern

Extended Trading

$0.68 +0.02 (+3.40%)

As of 09/11/2026 06:14 PM Eastern

Compare

ESLA vs. GUTS, AADI, COYA, ATRA, and ONCY

Should you buy Estrella Immunopharma stock or one of its competitors? Estrella Immunopharma's main competitors and comparable companies include Fractyl Health (GUTS), Aadi Bioscience (AADI), Coya Therapeutics (COYA), Atara Biotherapeutics (ATRA), and Oncolytics Biotech (ONCY). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Estrella Immunopharma compare to Fractyl Health?

Fractyl Health (NASDAQ:GUTS) and Estrella Immunopharma (NASDAQ:ESLA) are both small-cap healthcare companies, but which is the superior business? We will compare the two businesses based on the strength of their dividends, media sentiment, valuation, risk, profitability, analyst recommendations, earnings and institutional ownership.

Fractyl Health currently has a consensus price target of $5.50, indicating a potential upside of 759.38%. Estrella Immunopharma has a consensus price target of $8.00, indicating a potential upside of 1,112.86%. Given Estrella Immunopharma's higher probable upside, analysts plainly believe Estrella Immunopharma is more favorable than Fractyl Health.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Fractyl Health	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.40
Estrella Immunopharma	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Estrella Immunopharma's return on equity of 0.00% beat Fractyl Health's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Fractyl Health	N/A	-1,362.10%	-84.89%
Estrella Immunopharma	N/A	N/A	-328.72%

In the previous week, Fractyl Health had 16 more articles in the media than Estrella Immunopharma. MarketBeat recorded 18 mentions for Fractyl Health and 2 mentions for Estrella Immunopharma. Estrella Immunopharma's average media sentiment score of 0.43 beat Fractyl Health's score of 0.10 indicating that Estrella Immunopharma is being referred to more favorably in the news media.

Company	Overall Sentiment
Fractyl Health	Neutral
Estrella Immunopharma	Neutral

Estrella Immunopharma has lower revenue, but higher earnings than Fractyl Health. Estrella Immunopharma is trading at a lower price-to-earnings ratio than Fractyl Health, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Fractyl Health	$90K	1,131.95	-$140.95M	-$0.88	N/A
Estrella Immunopharma	N/A	N/A	-$13.06M	-$0.24	N/A

0.4% of Estrella Immunopharma shares are owned by institutional investors. 8.4% of Fractyl Health shares are owned by insiders. Comparatively, 5.8% of Estrella Immunopharma shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Fractyl Health has a beta of 2.34, suggesting that its stock price is 134% more volatile than the broader market. Comparatively, Estrella Immunopharma has a beta of 0.88, suggesting that its stock price is 12% less volatile than the broader market.

Summary

Fractyl Health beats Estrella Immunopharma on 7 of the 13 factors compared between the two stocks.

How does Estrella Immunopharma compare to Aadi Bioscience?

Estrella Immunopharma (NASDAQ:ESLA) and Aadi Bioscience (NASDAQ:AADI) are both small-cap healthcare companies, but which is the better business? We will compare the two companies based on the strength of their dividends, valuation, earnings, analyst recommendations, media sentiment, profitability, institutional ownership and risk.

Estrella Immunopharma has higher earnings, but lower revenue than Aadi Bioscience. Estrella Immunopharma is trading at a lower price-to-earnings ratio than Aadi Bioscience, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Estrella Immunopharma	N/A	N/A	-$13.06M	-$0.24	N/A
Aadi Bioscience	$25.07M	4.05	-$65.76M	-$2.35	N/A

Estrella Immunopharma has a net margin of 0.00% compared to Aadi Bioscience's net margin of -246.06%. Estrella Immunopharma's return on equity of 0.00% beat Aadi Bioscience's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Estrella Immunopharma	N/A	N/A	-328.72%
Aadi Bioscience	-246.06%	-71.87%	-57.28%

Estrella Immunopharma has a beta of 0.88, meaning that its share price is 12% less volatile than the broader market. Comparatively, Aadi Bioscience has a beta of 0.68, meaning that its share price is 32% less volatile than the broader market.

0.4% of Estrella Immunopharma shares are held by institutional investors. Comparatively, 52.1% of Aadi Bioscience shares are held by institutional investors. 5.8% of Estrella Immunopharma shares are held by company insiders. Comparatively, 37.3% of Aadi Bioscience shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

In the previous week, Estrella Immunopharma had 2 more articles in the media than Aadi Bioscience. MarketBeat recorded 2 mentions for Estrella Immunopharma and 0 mentions for Aadi Bioscience. Estrella Immunopharma's average media sentiment score of 0.43 beat Aadi Bioscience's score of 0.00 indicating that Estrella Immunopharma is being referred to more favorably in the media.

Company	Overall Sentiment
Estrella Immunopharma	Neutral
Aadi Bioscience	Neutral

Estrella Immunopharma currently has a consensus target price of $8.00, indicating a potential upside of 1,112.86%. Given Estrella Immunopharma's stronger consensus rating and higher probable upside, analysts plainly believe Estrella Immunopharma is more favorable than Aadi Bioscience.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Estrella Immunopharma	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Aadi Bioscience	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

Summary

Estrella Immunopharma beats Aadi Bioscience on 10 of the 14 factors compared between the two stocks.

How does Estrella Immunopharma compare to Coya Therapeutics?

Coya Therapeutics (NASDAQ:COYA) and Estrella Immunopharma (NASDAQ:ESLA) are both small-cap healthcare companies, but which is the better business? We will contrast the two businesses based on the strength of their risk, media sentiment, dividends, profitability, analyst recommendations, valuation, earnings and institutional ownership.

Estrella Immunopharma has lower revenue, but higher earnings than Coya Therapeutics. Coya Therapeutics is trading at a lower price-to-earnings ratio than Estrella Immunopharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Coya Therapeutics	$7.95M	12.93	-$21.23M	-$1.07	N/A
Estrella Immunopharma	N/A	N/A	-$13.06M	-$0.24	N/A

Coya Therapeutics has a beta of 0.61, suggesting that its share price is 39% less volatile than the broader market. Comparatively, Estrella Immunopharma has a beta of 0.88, suggesting that its share price is 12% less volatile than the broader market.

Coya Therapeutics currently has a consensus price target of $15.33, indicating a potential upside of 250.08%. Estrella Immunopharma has a consensus price target of $8.00, indicating a potential upside of 1,112.86%. Given Estrella Immunopharma's higher possible upside, analysts clearly believe Estrella Immunopharma is more favorable than Coya Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Coya Therapeutics	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.71
Estrella Immunopharma	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

39.8% of Coya Therapeutics shares are owned by institutional investors. Comparatively, 0.4% of Estrella Immunopharma shares are owned by institutional investors. 6.1% of Coya Therapeutics shares are owned by insiders. Comparatively, 5.8% of Estrella Immunopharma shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Estrella Immunopharma has a net margin of 0.00% compared to Coya Therapeutics' net margin of -270.22%. Estrella Immunopharma's return on equity of 0.00% beat Coya Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Coya Therapeutics	-270.22%	-52.05%	-46.34%
Estrella Immunopharma	N/A	N/A	-328.72%

In the previous week, Estrella Immunopharma had 1 more articles in the media than Coya Therapeutics. MarketBeat recorded 2 mentions for Estrella Immunopharma and 1 mentions for Coya Therapeutics. Coya Therapeutics' average media sentiment score of 0.94 beat Estrella Immunopharma's score of 0.43 indicating that Coya Therapeutics is being referred to more favorably in the media.

Company	Overall Sentiment
Coya Therapeutics	Positive
Estrella Immunopharma	Neutral

Summary

Coya Therapeutics and Estrella Immunopharma tied by winning 7 of the 14 factors compared between the two stocks.

How does Estrella Immunopharma compare to Atara Biotherapeutics?

Estrella Immunopharma (NASDAQ:ESLA) and Atara Biotherapeutics (NASDAQ:ATRA) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two businesses based on the strength of their analyst recommendations, risk, valuation, dividends, earnings, profitability, media sentiment and institutional ownership.

Estrella Immunopharma currently has a consensus target price of $8.00, indicating a potential upside of 1,112.86%. Atara Biotherapeutics has a consensus target price of $9.50, indicating a potential upside of 1.28%. Given Estrella Immunopharma's higher possible upside, equities analysts clearly believe Estrella Immunopharma is more favorable than Atara Biotherapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Estrella Immunopharma	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Atara Biotherapeutics	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	2.50

Estrella Immunopharma has a beta of 0.88, indicating that its share price is 12% less volatile than the broader market. Comparatively, Atara Biotherapeutics has a beta of 0.1, indicating that its share price is 90% less volatile than the broader market.

Atara Biotherapeutics has higher revenue and earnings than Estrella Immunopharma. Atara Biotherapeutics is trading at a lower price-to-earnings ratio than Estrella Immunopharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Estrella Immunopharma	N/A	N/A	-$13.06M	-$0.24	N/A
Atara Biotherapeutics	$120.77M	0.78	$32.69M	-$1.18	N/A

Estrella Immunopharma has a net margin of 0.00% compared to Atara Biotherapeutics' net margin of -269.42%. Estrella Immunopharma's return on equity of 0.00% beat Atara Biotherapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Estrella Immunopharma	N/A	N/A	-328.72%
Atara Biotherapeutics	-269.42%	-79.12%	-73.01%

In the previous week, Atara Biotherapeutics had 1 more articles in the media than Estrella Immunopharma. MarketBeat recorded 3 mentions for Atara Biotherapeutics and 2 mentions for Estrella Immunopharma. Atara Biotherapeutics' average media sentiment score of 1.10 beat Estrella Immunopharma's score of 0.43 indicating that Atara Biotherapeutics is being referred to more favorably in the news media.

Company	Overall Sentiment
Estrella Immunopharma	Neutral
Atara Biotherapeutics	Positive

0.4% of Estrella Immunopharma shares are held by institutional investors. Comparatively, 70.9% of Atara Biotherapeutics shares are held by institutional investors. 5.8% of Estrella Immunopharma shares are held by company insiders. Comparatively, 41.2% of Atara Biotherapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Summary

Atara Biotherapeutics beats Estrella Immunopharma on 9 of the 14 factors compared between the two stocks.

How does Estrella Immunopharma compare to Oncolytics Biotech?

Oncolytics Biotech (NASDAQ:ONCY) and Estrella Immunopharma (NASDAQ:ESLA) are both small-cap healthcare companies, but which is the superior investment? We will compare the two businesses based on the strength of their media sentiment, dividends, valuation, earnings, institutional ownership, risk, analyst recommendations and profitability.

Estrella Immunopharma is trading at a lower price-to-earnings ratio than Oncolytics Biotech, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Oncolytics Biotech	N/A	N/A	-$28.76M	-$0.34	N/A
Estrella Immunopharma	N/A	N/A	-$13.06M	-$0.24	N/A

Oncolytics Biotech currently has a consensus target price of $5.00, suggesting a potential upside of 570.69%. Estrella Immunopharma has a consensus target price of $8.00, suggesting a potential upside of 1,112.86%. Given Estrella Immunopharma's higher probable upside, analysts plainly believe Estrella Immunopharma is more favorable than Oncolytics Biotech.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Oncolytics Biotech	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	2.67
Estrella Immunopharma	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Estrella Immunopharma's return on equity of 0.00% beat Oncolytics Biotech's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Oncolytics Biotech	N/A	-2,185.97%	-442.99%
Estrella Immunopharma	N/A	N/A	-328.72%

In the previous week, Oncolytics Biotech had 2 more articles in the media than Estrella Immunopharma. MarketBeat recorded 4 mentions for Oncolytics Biotech and 2 mentions for Estrella Immunopharma. Oncolytics Biotech's average media sentiment score of 0.57 beat Estrella Immunopharma's score of 0.43 indicating that Oncolytics Biotech is being referred to more favorably in the media.

Company	Overall Sentiment
Oncolytics Biotech	Positive
Estrella Immunopharma	Neutral

6.8% of Oncolytics Biotech shares are held by institutional investors. Comparatively, 0.4% of Estrella Immunopharma shares are held by institutional investors. 0.1% of Oncolytics Biotech shares are held by insiders. Comparatively, 5.8% of Estrella Immunopharma shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Oncolytics Biotech has a beta of 1.15, meaning that its share price is 15% more volatile than the broader market. Comparatively, Estrella Immunopharma has a beta of 0.88, meaning that its share price is 12% less volatile than the broader market.

Summary

Oncolytics Biotech and Estrella Immunopharma tied by winning 6 of the 12 factors compared between the two stocks.

Get Estrella Immunopharma News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ESLA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

ESLA vs. The Competition

Export

Metric	Estrella Immunopharma	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$28.69M	$3.86B	$7.16B	$12.85B
Dividend Yield	N/A	3.66%	2.57%	11.71%
P/E Ratio	N/A	8.41	214.39	20.85
Price / Sales	N/A	1,378.88	633.80	90.72
Price / Cash	N/A	43.64	28.42	34.96
Price / Book	-2.44	15.12	10.33	6.21
Net Income	-$13.06M	-$22.86M	$3.50B	$358.54M
7 Day Performance	2.06%	-4.34%	-3.32%	-2.35%
1 Month Performance	-8.97%	0.54%	-0.53%	-3.23%
1 Year Performance	-37.77%	40.74%	23.51%	8.79%

Estrella Immunopharma Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
ESLA Estrella Immunopharma	1.7136 of 5 stars	$0.66 -2.0%	$8.00 +1,112.9%	-37.8%	$28.69M	N/A	N/A	N/A	Analyst Downgrade Short Interest Increase Gap Up
GUTS Fractyl Health	3.103 of 5 stars	$0.64 -6.6%	$5.50 +759.4%	-37.3%	$109.07M	$90K	N/A	102	Trending News
AADI Aadi Bioscience	N/A	$4.39 -4.6%	N/A	+104.5%	$108.42M	$25.07M	N/A	40
COYA Coya Therapeutics	2.1262 of 5 stars	$4.61 flat	$15.33 +232.6%	-27.6%	$108.14M	$7.95M	N/A	6
ATRA Atara Biotherapeutics	1.9856 of 5 stars	$9.91 -3.1%	$9.50 -4.1%	-22.6%	$102.69M	$6.19M	N/A	330	News Coverage Positive News Gap Up

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:ESLA) was last updated on 9/13/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Estrella Immunopharma (ESLA) Competitors

ESLA vs. GUTS, AADI, COYA, ATRA, and ONCY

How does Estrella Immunopharma compare to Fractyl Health?

Summary

How does Estrella Immunopharma compare to Aadi Bioscience?

Summary

How does Estrella Immunopharma compare to Coya Therapeutics?

Summary

How does Estrella Immunopharma compare to Atara Biotherapeutics?

Summary

How does Estrella Immunopharma compare to Oncolytics Biotech?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ESLA vs. The Competition

Estrella Immunopharma Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Estrella Immunopharma (ESLA) Competitors

ESLA vs. GUTS, AADI, COYA, ATRA, and ONCY

How does Estrella Immunopharma compare to Fractyl Health?

Do analysts rate GUTS or ESLA?

Is GUTS or ESLA more profitable?

Does the media prefer GUTS or ESLA?

Which has preferable earnings and valuation, GUTS or ESLA?

Do institutionals and insiders have more ownership in GUTS or ESLA?

Which has more risk & volatility, GUTS or ESLA?

Summary

How does Estrella Immunopharma compare to Aadi Bioscience?

Which has preferable valuation & earnings, ESLA or AADI?

Is ESLA or AADI more profitable?

Which has more volatility and risk, ESLA or AADI?

Do institutionals & insiders have more ownership in ESLA or AADI?

Does the media prefer ESLA or AADI?

Do analysts prefer ESLA or AADI?

Summary

How does Estrella Immunopharma compare to Coya Therapeutics?

Which has better earnings & valuation, COYA or ESLA?

Which has more volatility and risk, COYA or ESLA?

Do analysts rate COYA or ESLA?

Do insiders & institutionals have more ownership in COYA or ESLA?

Is COYA or ESLA more profitable?

Does the media favor COYA or ESLA?

Summary

How does Estrella Immunopharma compare to Atara Biotherapeutics?

Do analysts recommend ESLA or ATRA?

Which has more risk & volatility, ESLA or ATRA?

Which has better valuation & earnings, ESLA or ATRA?

Is ESLA or ATRA more profitable?

Does the media prefer ESLA or ATRA?

Do insiders and institutionals have more ownership in ESLA or ATRA?

Summary

How does Estrella Immunopharma compare to Oncolytics Biotech?

Which has stronger earnings & valuation, ONCY or ESLA?

Do analysts prefer ONCY or ESLA?

Is ONCY or ESLA more profitable?

Does the media favor ONCY or ESLA?

Do insiders and institutionals believe in ONCY or ESLA?

Which has more risk and volatility, ONCY or ESLA?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ESLA vs. The Competition

Estrella Immunopharma Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools